Notice of results and shareholder update

RNS Number : 3183Z

Allergy Therapeutics PLC

14 March 2012

 



Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

14 March 2012

Notice of results and shareholder update

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines will announce its interim results for the period ended 31 December 2011 on 30 March 2012.

The Company also announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will today release its annual report for the year ended 31 December 2011. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.

Balance Sheet as at 30 September 2011

	£ '000
Total Non Current Assets	17,969
Total Current Assets	15,229
Total Current Liabilities	(10,162)
Total Non Current Liabilities	(20,328)
Total Equity	2,708

Consolidated Income Statement for the 12 months ended 30 September 2011

	£'000
Revenue	42,156
(Loss) for the period	(1,028)

Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2011.

-Ends-

For further information

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson/ Clare Terlouw
FTI Consulting	[phone]
Simon Conway/ Susan Quigley

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

 

END

 

 

NORJIMLTMBBBMAT